PT - JOURNAL ARTICLE AU - Martin Broberg AU - Minna Ampuja AU - Samuel Jones AU - Tiina Ojala AU - Otto Rahkonen AU - Riikka Kivelä AU - James Priest AU - FinnGen AU - Hanna M. Ollila AU - Emmi Helle TI - Genomic and transcriptomic data analyses highlight <em>KPNB1</em> and <em>MYL4</em> as novel risk genes for congenital heart disease AID - 10.1101/2022.01.07.22268881 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.07.22268881 4099 - http://medrxiv.org/content/early/2022/01/08/2022.01.07.22268881.short 4100 - http://medrxiv.org/content/early/2022/01/08/2022.01.07.22268881.full AB - Congenital heart defects (CHD) are structural defects of the heart affecting approximately 1% of newborns. CHDs exhibit a complex inheritance pattern. While genetic factors are known to play an important role in the development of CHD, relatively few variants have been discovered so far and very few genome-wide association studies (GWAS) have been conducted. We performed a GWAS of general CHD and five CHD subgroups in FinnGen followed by functional fine-mapping through eQTL analysis in the GTEx database, and target validation in human induced pluripotent stem cell - derived cardiomyocytes (hiPS-CM) from CHD patients. We discovered that the MYL4-KPNB1 locus (rs11570508, beta = 0.24, P = 1.2×10−11) was associated with the general CHD group. An additional four variants were significantly associated with the different CHD subgroups. Two of these, rs1342740627 associated with left ventricular outflow tract obstruction defects and rs1293973611 associated with septal defects, were Finnish population enriched. The variant rs11570508 associated with the expression of MYL4 (normalized expression score (NES) = 0.1, P = 0.0017, in the atrial appendage of the heart) and KPNB1 (NES = -0.037, P = 0.039, in the left ventricle of the heart). Furthermore, lower expression levels of both genes were observed in human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CM) from CHD patients compared to healthy controls. Together, the results demonstrate KPNB1 and MYL4 as in a potential genetic risk loci associated with the development of CHD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from the Finnish Cultural Foundation (E.H, T.O. and M.B.), Finnish Foundation for Pediatric Research (E.H, T.O and M.B.), the Finnish Medical Foundation (E.H), Helsinki University (E.H), Helsinki University Hospital (E.H), and The Academy of Finland (E.H).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The coordinating Ethics Committee of the HUS Hospital District gave ethical approval for this work. Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesScRNAseq data files used for gene expression analysis will be made available in a public repository prior to publication.